Castle Biosciences Inc（CSTL）股票分析CSTLCastle Biosciences Inc

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC). It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Castle Biosciences Inc (CSTL) is a good buy right now due to its recent revenue growth of 20% year-over-year in Q2 2026, reaching $103.5 million, and a gross margin of 74.94%. Additionally, analysts have set price targets as high as $57, suggesting a potential upside of 72% from the current price. The main risk is the negative earnings per share (EPS) estimate of -0.38 for the next earnings report, which could impact investor sentiment.